A proposal from the US Centers for Medicare and Medicaid Services (CMS) could have negative consequences for a wide range of drugmakers, Bloomberg reported Tuesday.
A proposal from the US Centers for Medicare and Medicaid Services (CMS) could have negative consequences for a wide range of drugmakers, Bloomberg reported Tuesday.